Xencor (XNCR) Income from Continuing Operations (2013 - 2026)
Xencor (XNCR) posted quarterly Income from Continuing Operations of 128936000.0 for Q1 2026, down 164.95% year-over-year from 198527825.1 in Q1 2025, and down 1838.01% quarter-over-quarter from 6653000.0 in Q4 2025.
Powered by 
Analysis
Xencor (XNCR) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Income from Continuing Operations for 14 consecutive years, with 128936000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 164.95% year-over-year to 128936000.0; the TTM figure through Mar 2026 stood at 172441000.0 (up 18.31% YoY), while the FY2025 annual figure was 92137000.0, up 61.05% from the prior year.
- Income from Continuing Operations declined to 128936000.0 in Q1 2026 per XNCR's latest filing, from 6653000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 25782000.0 in Q1 2022 and bottomed at 128936000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 42206411.76 across 5 years, with a median of 46200000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 259.43% — and 2023, when it slumped 327.17%.
- Xencor's Income from Continuing Operations stood at 12042000.0 in 2022, then sank by 118.49% to 26310000.0 in 2023, then sank by 75.6% to 46200000.0 in 2024, then soared by 85.6% to 6653000.0 in 2025, then plunged by 1838.01% to 128936000.0 in 2026.
- Business Quant data shows XNCR's Income from Continuing Operations at 128936000.0 in Q1 2026, 6653000.0 in Q4 2025, and 6027000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | -21.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.72 Mn |
| Mar 31, 2026 | -128.94 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -30.78 Mn |
| Mar 31, 2025 | -48.67 Mn |
| Dec 31, 2024 | -46.20 Mn |
| Sep 30, 2024 | -47.44 Mn |
| Jun 30, 2024 | -68.78 Mn |
| Mar 31, 2024 | -74.12 Mn |
| Dec 31, 2023 | -26.31 Mn |
| Sep 30, 2023 | -24.27 Mn |
| Jun 30, 2023 | -26.00 Mn |
| Mar 31, 2023 | -57.85 Mn |
| Dec 31, 2022 | -12.06 Mn |
| Sep 30, 2022 | -32.77 Mn |
| Jun 30, 2022 | -28.00 Mn |
| Mar 31, 2022 | 26.47 Mn |
| Dec 31, 2021 | 73.06 Mn |
| Sep 30, 2021 | -40.19 Mn |